NexGel Q2 revenue $3.69 million, net loss $2.87 million; proxy proposals fell short
NexGel reported second quarter 2026 revenue of $3.69 million and a net loss of $2.87 million, and said its integration and expansion into the surgical channel have moved more slowly than expected. Shareholders did not give sufficient support to the proposed increase in authorized shares and reverse stock split, and the company plans to resubmit them as standalone proposals with completion expected in late September.
Key points
- Q2 2026 revenue of $3.69 million and net loss of $2.87 million, including $756,554 of BioNX intangible amortization and $273,710 of one-time transaction expenses
- BioNX Surgical backlog of approximately $795,000 due to supply chain constraints
- Proxy proposals for increased authorized shares and reverse split lacked sufficient support; resolicitation timeline anticipates completion in late September
- Investor update call expected on or around September 15, 2026
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 17, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.